INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclero
Date postedNovember 12, 2023
The Woodlands, Texas, November 12, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hocanalysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® (sotagliflozin) use in heart failure (HF) and major adverse cardiovascular events (MACE) related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events. The data were shared in an oral presentation by Rahul Aggarwal, M.D., Brigham and Women’s Hospital, Boston, Massachusetts, at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Pennsylvania.